Covered recipient · General Payments record
PHILIP FORTUNATO SPADAFORA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$3,442.76
- Reported across 168 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $236.07 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $105.26 | 3 |
| ABBVIE INC. | $36.09 | 2 |
| Exact Sciences Corporation | $22.04 | 1 |
| EVOKE PHARMA, INC. | $21.57 | 1 |
| Novo Nordisk AS | $20.60 | 1 |
| Lilly USA, LLC | $16.22 | 1 |
| GlaxoSmithKline, LLC. | $14.29 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.32 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106143646 | CMS |
| ABBVIE INC. | $21.77 | 07/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106143648 | CMS |
| EVOKE PHARMA, INC. | $21.57 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127774035 | CMS |
| Exact Sciences Corporation | $22.04 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114912384 | CMS |
| GENZYME CORPORATION | $35.94 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139967397 | CMS |
| GENZYME CORPORATION | $31.82 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139967425 | CMS |
| GENZYME CORPORATION | $37.50 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139967439 | CMS |
| GlaxoSmithKline, LLC. | $14.29 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116306339 | CMS |
| Lilly USA, LLC | $16.22 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135318551 | CMS |
| Novo Nordisk Inc | $20.60 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097600525 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.